1. Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer

3. This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Treatment Options for mCRPC

5. 5 FDA-Approved Therapies Can Be Used in Any Sequence

6. Case 1: 75-Year-Old Caucasian Man

7. Case 1 (cont)

8. Case 1: Patient Bone Scans

9. Pattern of Disease in mCRPC Over Time

10. Radium-223

11. ALSYMPCA: Randomized, Phase 3 Trial of Radium-223 in Symptomatic mCRPC

12. ALSYMPCA Subgroup Analysis by Prior Docetaxel Therapy

13. Abiraterone in Chemotherapy-Naive mCRPC COU-AA-302 Trial

14. Enzalutamide in Chemotherapy-Naive mCRPC PREVAIL Trial

15. Phase 3b Expanded Access Trial of Radium-223

16. Radium-223 Phase 3b Trial: Concomitant Use of Abiraterone or Enzalutamide

17. Ongoing Combination Therapy Trials

18. OS in ALSYMPCA by Bisphosphonate Use

19. OS in ALSYMPCA by Baseline Opioid Use

20. Case 1 Wrap-Up: Patient's PSA Response to First-Line Radium-223

21. Patient's Responses on PET Scan and Functional MRI

22. Case 2: 59-Year-Old Caucasian Man

23. Case 2: Bone Scan, September 2015

24. Case 2 (cont)

25. Case 2: Bone Scan, January 2017

26. Case 2: Treatment Options

27. Case 2: Conclusion

28. LATITUDE Trial: Early Abiraterone in Newly Diagnosed mHNPC

29. STAMPEDE Trial: Early Abiraterone in Newly Diagnosed mHNPC

30. ARASENS: Randomized, Double-Blind, Phase 3 Trial of ODM-201* in mHSPC

31. Tumor Genetic Sequencing

32. AR-V7 Status and Resistance to Enzalutamide and Abiraterone

33. New Approaches and Future Directions

34. Multidisciplinary Approach to mPC: Perspective of the Community Urologist

35. Concluding Remarks

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)

39. Abbreviations (cont)